Alcohol and Sexual Communication Among Couples in the Laboratory
University of Colorado, Denver · with National Institute on Alcohol Abuse and Alcoholism (NIAAA) · NCT06865872
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 21–65 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 480
- US sites recruiting
- 1
- Study start
- April 18, 2025
- Record last updated
- October 28, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Intimate Partner Sexual Violence (IPSV) is a significant and understudied public health problem among couples, yet little is known about factors that contribute to IPSV perpetration. This proposal aims to determine the acute effect of alcohol and sexual communication on IPSV. In this study, 240 couples who drink alcohol will be recruited from the Metro-Denver area. Upon arrival to the laboratory, a trained research assistant will check the participant's ID, verify that they adhered to the pre-session guidelines, administer a breath test to ensure a breath alcohol content (BrAC) of 0.00 and conduct a field sobriety test. They will also obtain informed consent for each member of the couple separately. Female participants will take a pregnancy test to ensure a negative result. All participants will complete measures to reverify eligibility criteria and be weighed to determine their correct alcohol dose. Partners will separately complete a baseline survey measuring demographic factors, alcohol use, sexual communication, and daily experiences. After completing the survey, participants will be assigned a beverage condition (alcohol or no-alcohol control) and couples will be randomly assigned to a communication condition (direct verbal or indirect verbal). Participants will be seated in a room separate from their partner, where they will drink an alcoholic or no-alcohol control beverage. Upon reaching a breath alcohol content (BrAC) of .07, or immediately after drinking in the No-Alcohol control condition, participants will complete a laboratory assessment of sexual violence. The main hypotheses are: (1) one's alcohol use will increase IPSV toward partners who are also drinking, (2) one's alcohol use will increase IPSV among partners who use indirect, relative to direct, communication, and (3) actor alcohol use will increase IPSV toward partners who are also drinking and use indirect, relative to direct, communication.
Being studied: Direct Communication; Indirect Communication; Alcohol (Ethanol); No-Alcohol Control
Conditions: Alcohol Intoxication; Intimate Partner Violence (IPV); Communication
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Provision of signed and dated informed consent form.
- Stated willingness to comply with all study procedures and lifestyle considerations.
- Both partners must identify as cisgender via self-report on the Baseline Questionnaire.
- At least one partner within the couple must be a man via self-report on the Baseline Questionnaire.
- Both partners must be between 21 and 65 years old, verified by a photo ID.
- In an intimate relationship lasting at least one month in which they engaged in sexual activity at least once in the past month with their partner via self-report on the Baseline Questionnaire.
- Both partners must report that they consumed a weight-based amount of alcohol that is equal to or greater than the dose to be administered in the lab at least three times during the past year via self-report on question #5 of the NIAAA Alcohol Consumption Measure.
Please contact clinical site for additional inclusion criteria.
Exclusion Criteria
- Treatment for Alcohol or Drug Use: currently being treated for alcohol, or drug problems; currently interested in seeking treatment for drinking or drug use via self-report.
- Any medical or psychiatric condition, as well as current use of a medication, that would contraindicate alcohol administration via self-report:
- Cardiac Pacemaker
- Asthma: emergency room visit related to asthma in the past year; use of inhaler more frequently when drinking alcohol; use of oral steroid treatments for asthma in the past year
- Head Injury: any past serious head injuries
- Acute Psychiatric Symptomatology: elevated psychological distress as indicated by a score greater than 65 on the Brief Symptom Inventory
- Self-report that a participant is trying to get pregnant, currently pregnant, or currently breastfeeding or a positive pregnancy test.
- Combined height and weight that is either less than 6 feet tall and over 230 lbs, or over 250 lbs and over 6 ft tall as measured during the lab visit.
Please contact clinical site for additional exclusion criteria.
Recruiting US locations
University of Colorado Anschutz Medical Campus
Aurora, CO 80045
Site contact: Ruschelle M Leone, PhD · 303-724-7052 · ruschelle.leone@cuanschutz.edu
Study contacts (from the official record)
- Ruschelle M Leone, PhD · 303-724-7052 · ruschelle.leone@cuanschutz.edu
Similar studies in Colorado
All healthy volunteers studies in Colorado →- RecruitingHealthy volunteersPhase 1/Phase 2
A Study of BLB-201 RSV Vaccine in Infants and Children
Blue Lake Biotechnology Inc.
- Location
- Aurora, CO + 13 other US sites
- Eligibility basics
- Ages 6 mo–5
- RecruitingHealthy volunteersPhase 1
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
Mabylon AG
- Location
- Aurora, CO + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
Novo Nordisk A/S
- Location
- Aurora, CO + 4 other US sites
- Eligibility basics
- Ages 18–64 · Men only
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Novartis Pharmaceuticals
- Location
- Aurora, CO + 18 other US sites
- Eligibility basics
- Ages 18–100